Trial of Aromatase Inhibition in Lymphangioleiomyomatosis
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in
postmenopausal women with Lymphangioleiomyomatosis (LAM) will prevent or delay progression of
lung disease and result in a decrease in the rate of decline in FEV1